TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ? (umbralisib), Ublituximab, and Venetoclax

Investor Relations Email:?ir@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 4 Media Relations: Email:?media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 6 |